Rosetta Genomics' Cancer Origin Test Highlighted at Landmark CUP Foundation Seminar 2014
March 21 2014 - 12:15PM
Marketwired
Rosetta Genomics' Cancer Origin Test Highlighted at Landmark CUP
Foundation Seminar 2014
International Medical Seminar Highlights the Management,
Treatment, Diagnosis and Future Perspectives of Cancer of Unknown
Primary
PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Mar 21, 2014)
- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, reports that the
Company is sponsoring and participating in the CUP Foundation
seminar 2014 taking place from March 21-22 in London,
England. This international medical seminar highlights the
management, treatment, diagnosis and future perspectives of Cancer
of Unknown Primary (CUP) by some of the world's leading clinicians
for CUP and is supported by the European Society for Medical
Oncology (ESMO) and the European School of Oncology.
E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics' Chief
Medical Officer, delivered a presentation on the role of molecular
profiling and new diagnostic technologies in discussion Module Two
entitled, "Diagnostic challenges, subsets, and prognosis," taking
place on Friday, March 21st from 11:30 a.m. until 1:30 p.m. local
time.
"We are delighted to participate in and support this important
seminar in which we demonstrated how molecular profiling and other
new diagnostic technologies can help to resolve the diagnostic
conundrum of CUP. By accurately identifying the primary tumor
origin, physicians will be able to make more informed decisions to
select the best treatment choices to optimize patient outcomes. We
applaud the efforts of the CUP Foundation in hosting this meeting,
which provided valuable information and resources to patients,
physicians and care givers," commented Dr. Wassman.
Rosetta's Cancer Origin Test™ is the company's second-generation
microRNA-based diagnostic for the identification of the primary
site of metastatic cancer, specifically metastatic cancer of
CUP. The Cancer Origin Test utilizes custom-designed
microarray technology to identify 49 possible cancer origins with
very high accuracy using 64 microRNAs. These 49 origins include
carcinomas, soft tissue tumors, lymphoma and other
malignancies.
About Rosetta Cancer Testing Services Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta
Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta's assays are designed to provide objective
diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S.
alone, Rosetta Genomics estimates that 200,000 patients a year may
benefit from the Rosetta Cancer Origin Test™, 60,000 from the
Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer
Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The
Company's assays are offered directly by Rosetta Genomics in the
U.S., and through distributors around the world. For more
information, please visit www.rosettagenomics.com. Parties
interested in ordering the test can contact Rosetta Genomics at
(215) 382-9000 ext. 309.
About Rosetta Genomics Rosetta develops and commercializes a
full range of microRNA-based molecular diagnostics. Founded in
2000, Rosetta's integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human
microRNAs. Building on its strong patent position and proprietary
platform technologies, Rosetta is working on the application of
these technologies in the development and commercialization of a
full range of microRNA-based diagnostic tools. Rosetta's cancer
testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab.
Forward-Looking Statement Disclaimer Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, constitute forward-looking statements for the purposes
of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a
result of various important factors, including those risks more
fully discussed in the "Risk Factors" section of Rosetta's Annual
Report on Form 20-F for the year ended December 31, 2012 as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
Company Contact: Rosetta Genomics Ken Berlin President & CEO
(609) 419-9003 investors@rosettagenomics.com Investor Contacts: LHA
Anne Marie Fields (212) 838-3777 afields@lhai.com or Bruce Voss
(310) 691-7100 bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024